P2RY12 and Stroke: The current report is what we believe to be the first pharmacogenetic study with an in vivo thrombotic outcome and shows that P2Y12 antagonism with oral ticagrelor improves stroke outcomes in hPAR4Ala/Ala mice; however, under these same conditions, no benefit was observed in the hPAR4Thr/Thr mice.